anti-DLL3 ADC ZL-1310
An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and linked to an as of yet unelucidated cytotoxic agent, with potential immunostimulating and antineoplastic activities. Upon administration, anti-DLL3 ADC ZL-1310 targets and binds to DLL3 found on DLL3-expressing tumor cells. Upon internalization, the cytotoxic agent causes cell death in DLL3-expressing tumor cells through an as of yet unknown mechanism of action. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
Synonym: | ADC SC-002 anti-DLL3 antibody-drug conjugate ZL-1310 |
---|---|
Code name: | YL 212 YL-212 YL212 ZL 1310 ZL-1310 ZL1310 |